SEC Comment Letter 0000000000-24-006882 to ASLAN Pharmaceuticals Ltd (CIK 0001722926)
ASLAN Pharmaceuticals Ltd (CIK 0001722926)
Date: June 14, 2024 · CIK: 0001722926 · Accession: 0000000000-24-006882
AI Filing Summary & Sentiment
File numbers found in text: 333-280145
Letter
United States securities and exchange commission logo June 14, 2024 Carl Firth Chief Executive Officer ASLAN Pharmaceuticals Limited 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 Re:ASLAN Pharmaceuticals Limited Registration Statement on Form F-3 Filed June 12, 2024 File No. 333-280145 Dear Carl Firth: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez
Show Raw Text
United States securities and exchange commission logo
June 14, 2024
Carl Firth
Chief Executive Officer
ASLAN Pharmaceuticals Limited
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
Re:ASLAN Pharmaceuticals Limited
Registration Statement on Form F-3
Filed June 12, 2024
File No. 333-280145
Dear Carl Firth:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carlos Ramirez